In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Predictive factors for recovery of left ventricular systolic function in stress cardiomyopathy

Session Poster Session 3

Speaker Yutaka Kajikawa

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : Y Kajikawa (Fukuyama,JP), M Ikeda (Fukuyama,JP), A Ueda (Fukuyama,JP), M Hirota (Fukuyama,JP)

Authors:
Y Kajikawa1 , M Ikeda1 , A Ueda1 , M Hirota1 , 1Fukuyama Medical Center - Fukuyama - Japan ,

Citation:

Introduction
Stress cardiomyopathy is a reversible systolic dysfunction of the left ventricle that is characterized by defined wall motion abnormalities in the absence of significant coronary stenosis. It is prevalent among elderly women, and often arises following a physical or emotionally stressful event. Little is known about the prognostic factors affecting the recovery of systolic function.
Objective
The present study aimed to identify factors affecting the recovery of left ventricular systolic function.
Materials and Methods
This retrospective review analyzed the electronic medical records of 41 patients diagnosed with stress cardiomyopathy at our Medical Centre between April 2008 and March 2018.
Results
The median time to the recovery of ejection fraction (EF) was 7.0 days. Demographic and clinical factors were compared between groups with early recovery (= 7 days; group E) and late recovery (> 8 days; group L).
Age (75.5 ± 10.7 vs. 73.9 ± 14.6 years), physical stress (89.1% vs. 72.3%), emotional stress (10.6% vs. 27.3%) and in-hospital death (15.8% vs. 9.1%) did not differ significantly between the L and the E groups, respectively. Heart rate and the prevalence of Killip class > 2 heart failure upon admission was higher in the L, than the E group (101.1 ± 24.4 vs. 86.2 ± 24.2 bpm, p < 0.05 and  13% vs. 6%, p < 0.01), respectively.
Echocardiography revealed significantly lower left ventricular ejection fraction in the L, than the E group (38.4 ± 7.0% vs. 49.6 ± 13.0% p < 0.001).
Laboratory findings showed significantly higher C reactive protein (7.67 ± 6.49 vs. 4.90 ± 8.97 mg/dL, p < 0.05) and creatinine phosphokinase (556.1 ± 864.3 vs. 127.3 ± 162.2 IU/L, p < 0.01) and significantly lower hemoglobin (10.27 ± 2.23 vs. 11.51 ± 1.95 g/dL, p < 0.05) and LDL-cholesterol (80.5 ± 26.9 vs. 111.9 ± 41.6 mg/dL, p < 0.05) in the L, than in the E group.
Significantly more patients were medicated with warfarin/Directly acting oral anticoagulants (DOACs) (42.1% vs. 18.2%), ß-blockers (47.4% vs. 31.8%), catecholamine (42.1% vs. 13.6%) and required non-invasive positive pressure ventilation (NIPPV)(26.3% vs. 0.0%) in the L, than the E group (p < 0.05 for all).
Conclusion
Severe cardiac dysfunction at onset and triggering septic or inflammatory disease were seen more commonly in the L group.  Although more patients in the L group required warfarin/DOAC, ß-blockers, catecholamine and even NIPPV more often than the E group, the prognosis was fairly good for both groups with stress cardiomyopathy.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are